Josée Golay, Greta Ubiali, Martino Introna. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. haematol [Internet]. 2017Sep.30 [cited 2024Nov.22];102(10):e400-e403. Available from: https://haematologica.org/article/view/8235